Obinutuzumab Biosimilar, Endotoxin 0.05 EU/mg | Catalog C057P.05

Obinutuzumab Biosimilar, Endotoxin 0.05 EU/mg. The research grade Obinutuzumab biosimilar protein is for research use only (RUO). Recombinant human IgG1 isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.

Product Specifications

Catalog No.	C057P.05
Product Name	Obinutuzumab Biosimilar, Endotoxin 0.05 EU/mg
Supplier Name	Syd Labs, Inc.
Brand Name	Syd Labs
Synonyms	B-lymphocyte antigen CD20, MS4A1, B1, Bp35, CVID5, LEU-16, MS4A2, S7, membrane spanning 4-domains A1, FMC7
Summary	Recombinant Humanized IgG1 Monoclonal Antibody.
Isotype	Human IgG1 kappa.
Source/Host	Produced in the obinutuzumab biosimilar CHO stable cell line.
Specificity	Specifically binds to human type II CD20 antibodies.

Properties & Storage

Applications	ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by obinutuzumab.
Formulation	0.2 μM filtered solution, pH 6.0, no stabilizers or preservatives.
Endotoxin	< 0.05 EU per 1 mg of the protein by the LAL method.
Purity	>95% by SDS-PAGE under reducing conditions and HPLC.
Shipping	Shipped with ice pack. Store immediately at recommended temperature.
Storage	12 months from receipt at -20 to -70°C; 1 month at 2 to 8°C. Avoid freeze-thaw cycles.

Background & Description

Obinutuzumab Biosimilar uses the same protein sequences as the therapeutic antibody obinutuzumab.

Obinutuzumab is an antineoplastic CD20 antibody used to treat untreated chronic lymphocytic leukemia in combination with chlorambucil.

In contrast to rituximab, which is a classic type I CD20 antibody, obinutuzumab binds to type II CD20 antibodies. This allows obinutuzumab to have a much higher induction of antibody-dependent cytotoxicity and a higher direct cytotoxic effect than the classic CD20 antibodies.